A bacterial population regulator for promoting Staphylococcus hominis population

Abstract

To provide a novel bacterial amount regulator for enhancing the amount of bacteria of Staphylococcus hominis.SOLUTION: This regulator contains Actinidia deliciosa extract and / or Citrus junos extract as an active ingredient.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a bacterial load regulator for promoting the bacterial load of Staphylococcus hominis. [Background technology]

[0002] In recent years, cosmetics containing, as an active ingredient, bacteria having beneficial effects on the human body have been proposed (Patent Document 1). For example, Patent Document 2 discloses the use of Staphylococcus hominis as an active ingredient in the treatment of atopic dermatitis.

[0003] Additionally, technology that specifically controls certain bacteria that have a beneficial effect on skin conditions is also attracting attention.

[0004] Incidentally, Patent Document 3 discloses that kiwi extract can be used to improve wrinkles by controlling the activity of heparanase present in the skin.

[0005] Furthermore, Patent Document 4 discloses that kiwi extract has the effect of alleviating hot flashes. Furthermore, Patent Document 5 discloses that a hardy kiwifruit preparation has an improving effect on atopic dermatitis. Furthermore, Patent Document 6 discloses the whitening effect of kiwi extract.

[0006] Furthermore, Patent Document 7 discloses that the uses of yuzu extract include the ability to scavenge active oxygen, inhibit the production of lipid peroxides, and inhibit the production of melanin itself. Furthermore, Patent Document 8 discloses that the combination of yuzu extract and a tocopherol compound has the effects of improving dark circles, preventing rough skin, improving keratin, preventing aging, and whitening. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Japanese Patent Application Publication No. 09-020638 [Patent Document 2] Special Publication No. 2018-515488 [Patent Document 3] Japanese Patent Application Laid-Open No. 2016-169238 [Patent Document 4] Re-tabled publication 2012 / 133825 [Patent Document 5] Special Publication No. 2008-531584 [Patent Document 6] Japanese Patent Application Laid-Open No. 2003-160463 [Patent Document 7] Japanese Patent Application Laid-Open No. 2002-068953 [Patent Document 8] Japanese Patent Application Publication No. 11-290024 Summary of the Invention [Problem to be solved by the invention]

[0008] In view of the above-mentioned prior art, an object of the present invention is to provide a novel technique for specifically controlling the amount of a specific bacterial cell.

[0009] As a result of extensive research efforts, the present inventors have discovered that kiwi extract and / or yuzu extract has an effect of promoting the bacterial count of Staphylococcus hominis, and have completed the present invention. [Means for solving the problem]

[0010] The present invention, which solves the above-mentioned problems, provides a bacterial count regulator for promoting the bacterial count of Staphylococcus hominis, comprising a kiwi extract and / or a yuzu extract.

[0011] In this specification, the concept of "promoting bacterial count" includes both increasing bacterial count and suppressing a decrease in bacterial count.

[0012] In a preferred embodiment of the present invention, the bacterial load regulator is a composition for external application to the skin.

[0013] The present invention also relates to a composition for external application to the skin for regulating the bacterial load of Staphylococcus hominis, which comprises a kiwi extract and / or a yuzu extract.

[0014] In a preferred embodiment of the present invention, the above-mentioned external skin composition is for preventing or improving rough skin that is not caused by atopic dermatitis and increased sebum production in skin that is not caused by atopic dermatitis.

[0015] In a preferred embodiment of the present invention, the above-mentioned topical skin composition is used to improve skin conditions caused by age spots, dullness, pigmentation, post-inflammatory pigmentation, sun spots, or an increase in the number of noticeable pores.

[0016] In a preferred embodiment of the present invention, the above-mentioned external skin composition is used to improve wrinkles.

[0017] In a preferred embodiment of the present invention, the composition for external use on the skin is a cosmetic.

[0018] In a preferred embodiment of the present invention, the above-mentioned composition for external use on the skin is a pharmaceutical product.

[0019] The present invention also provides a method for regulating the bacterial count on the skin, which comprises applying a kiwi extract and / or a yuzu extract to the skin to promote the bacterial count of Staphylococcus hominis. [Effects of the Invention]

[0020] According to the present invention, an agent having an excellent effect of promoting the bacterial count of Staphylococcus hominis can be provided. [Brief explanation of the drawings]

[0021] [Figure 1] 1 is a graph showing the results of comparing Example 1-1 with a comparative example. [Figure 2] 1 is a graph showing the results of comparing Example 1-2 with a comparative example. [Figure 3] 1 is a graph showing the results of comparing Example 2 with the comparative example. [Figure 4] <Test Example 2> Graph showing the results of the amount of S. hominis in the application test. [Figure 5] <Test Example 2> This is a diagram showing the test results regarding the influence of Staphylococcus hominis (S. hominis) on the number of noticeable pores. [Figure 6] <Test Example 2> This is a diagram showing the test results regarding the effect of Staphylococcus hominis (S. hominis) on the melanin index. [Figure 7] <Test Example 2> This is a diagram showing the test results regarding the effect of Staphylococcus hominis (S. hominis) on the number of wrinkles. DETAILED DESCRIPTION OF THE INVENTION

[0022] The bacterial count regulator of the present invention for promoting the bacterial count of Staphylococcus hominis contains a kiwi extract and / or a yuzu extract as an active ingredient.

[0023] The kiwi extract may be purchased and used from a commercially available company that handles plant raw materials. In addition, kiwi extract can be produced by extracting kiwi fruit that grows wild or is grown in Japan.

[0024] When extracting a kiwi extract, it is preferable to process the kiwi fruit in advance by crushing or shredding it so as to improve the extraction efficiency.

[0025] The extract can be obtained by the following method. 1 to 30 parts by mass of a solvent is added to 1 part by mass of kiwi fruit or its dried product, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed if desired. The solvent is then removed by, for example, vacuum concentration. The resulting mixture is then fractionated and purified using column chromatography packed with silica gel or ion exchange resin to obtain the desired extract.

[0026] The extraction solvent is preferably a polar solvent, and suitable examples include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol, polypropylene glycol, and 1,3-butylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. Among these, 1,3-butylene glycol is a preferred extractant.

[0027] The yuzu extract may be purchased and used from a commercially available company that handles plant raw materials. In addition, the yuzu extract can be produced by extracting the fruit of yuzu trees that grow wild or are cultivated in Japan, or a dried product thereof.

[0028] Furthermore, when extracting a yuzu extract, it is preferable to process the yuzu fruit or a dried product thereof in advance by crushing or shredding it so as to improve the extraction efficiency.

[0029] The extract can be obtained by the following method. 1 to 30 parts by mass of a solvent is added to 1 mass of yuzu fruit or its dried product or its dried product, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed if desired, followed by removal of the solvent by vacuum concentration or the like. The desired extract can then be obtained by fractionation and purification using column chromatography packed with silica gel or ion exchange resin.

[0030] The extraction solvent is preferably a polar solvent, and suitable examples include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol, polypropylene glycol, and 1,3-butylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. Among these, 1,3-butylene glycol is a preferred extractant.

[0031] The bacterial load regulator of the present invention can be in the form of a composition for external application to the skin or a composition for oral administration. In particular, the bacterial load regulator of the present invention is preferably in the form of a composition for external application to skin.

[0032] Suitable examples of external skin compositions include cosmetics and pharmaceuticals.

[0033] Among these, it is preferable to use the cosmetic in the form of a cosmetic that can be used continuously, such as a lotion, emulsion, serum, cream, gel, sun care product, etc.

[0034] The content of kiwi extract and / or yuzu extract in the composition for external use on skin is 0.05% by mass or more, preferably 0.08% by mass or more, and more preferably 0.1% by mass or more. The content of kiwi extract and / or yuzu extract in the composition for external use on skin is preferably 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0035] In the examples described below, it has been shown that the bacterial load-promoting effect of Staphylococcus hominis is exerted on the skin of patients who do not have atopic dermatitis. Therefore, the active ingredient of the present invention is preferably applied to patients who do not have atopic dermatitis. In a more preferred embodiment of the present invention, the active ingredient of the present invention is intended for use in patients who do not have atopic dermatitis and who are aware of dry skin or skin discomfort caused by dry skin.

[0036] As will be shown in the examples below, by increasing the amount of Staphylococcus hominis bacteria, it is possible to prevent or improve skin conditions caused by an increase in the number of noticeable pores.

[0037] Here, examples of skin conditions caused by an increase in the number of noticeable pores include rough skin and increased sebum production.

[0038] As mentioned above, the bacterial load-promoting effect of Staphylococcus hominis is exerted on the skin of patients without atopic dermatitis. Therefore, the active ingredient of the present invention is preferably used to improve rough skin that is not caused by atopic dermatitis, or increased sebum production in skin that is not caused by atopic dermatitis.

[0039] Furthermore, as will be shown in the examples below, the amount of melanin decreases as the amount of Staphylococcus hominis bacteria increases. Therefore, the active ingredient of the present invention can be used to improve age spots, dullness, pigmentation, post-inflammatory pigmentation, and sun spots.

[0040] Here, in the examples described below, it is shown that promoting the bacterial count of Staphylococcus hominis reduces existing melanin. That is, the active ingredient of the present invention is particularly preferably used for improving pre-existing spots, dullness, pigmentation, post-inflammatory pigmentation, and sun spots.

[0041] As will be shown in the examples below, the number of wrinkles decreases by increasing the bacterial count of Staphylococcus hominis. Therefore, the active ingredient of the present invention can be used to improve wrinkles by promoting the bacterial count of Staphylococcus hominis. In particular, the active ingredient of the present invention is particularly preferably used for improving pre-existing wrinkles.

[0042] Furthermore, by using it in combination with kiwi extract and / or yuzu extract, it is possible to provide a composition for external use on the skin that specifically controls the amount of the above-mentioned bacterial cells and exhibits the above-mentioned skin condition improving effect in a complex manner.

[0043] When provided in the form of a skin external composition, the composition is not particularly limited, and it may contain any commonly used optional ingredients as long as it does not impair the effects of the present invention. Such optional ingredients include, for example, oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ivotaro wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum, mica, citric acid ... hydrocarbons such as crystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, sebacillus acidophilus, and the like; Synthetic ester oils such as di-2-ethylhexyl phosphate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate, and other oils; fatty acid soaps (sodium laurate, sodium palmitate, etc.) anionic surfactants such as potassium lauryl sulfate and alkyl sulfate triethanolamine ether; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride and laurylamine oxide; amphoteric surfactants such as imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfobetaine, etc.), and acyl methyl taurine;Sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitol fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic (registered trademark) types, Preferred examples of such surfactants include nonionic surfactants such as POE·POP alkyl ethers (POE·POP 2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, and alkyl glucosides; polyhydric alcohols such as polyethylene glycol, glycerin, erythritol, sorbitol, maltitol, propylene glycol, and 2,4-hexanediol; moisturizing ingredients such as sodium pyrrolidonecarboxylate, lactic acid, and sodium lactate; para-aminobenzoic acid-based UV absorbers; anthranilic acid-based UV absorbers; salicylic acid-based UV absorbers; cinnamic acid-based UV absorbers; benzophenone-based UV absorbers; sugar-based UV absorbers; and UV absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.

[0044] When an oral composition is prepared, it is preferable to prepare a food composition containing the active ingredient of the present invention. Specifically, it can be in the form of a supplement having the dosage form of a general food, tablet, granule, drink, or the like.

[0045] Here, the contents and content ratios of kiwi extract and / or yuzu extract in the oral composition can be determined mutatis mutandis from the description of the preferred embodiment of the topical skin composition described above.

[0046] When the composition is prepared as an oral composition, optional ingredients may be appropriately blended within the range that does not impair the effects of the present invention.

[0047] The present invention can also provide a method for regulating the bacterial load on the skin, which comprises applying a kiwi extract and / or a yuzu extract to the skin.

[0048] Here, the method for controlling the bacterial load on the skin of the present invention is a non-therapeutic method, preferably a cosmetic method, more preferably a cosmetic method for the skin.

[0049] According to the method for regulating the amount of bacteria on the skin of the present invention, the amount of a specific bacterial cell is specifically controlled.

[0050] The above-mentioned contents can be applied to the preferred embodiment of the method for adjusting the bacterial count on the skin of the present invention. [Example]

[0051] The bacterial count-regulating ability of kiwi extract and / or yuzu extract was investigated below.

[0052] <Test Example 1> Study on the change in Staphylococcus hominis levels due to kiwi extract and yuzu extract

[0053] (1) Preparation of bacterial suspension First, Staphylococcus hominis GTC485 strain (hereinafter simply referred to as S. hominis) was cultured at 37°C under aerobic conditions using 802 medium (see the table below) at pH 7.0. Here, Staphylococcus hominis GTC485 strain was purchased through the Japanese Society for Bacteriology (postal code: 170-0003, address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo, Japan, Oral Health Association).

[0054] The OD660 of the cultured bacterial suspension was measured using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)), and the bacterial concentration was calculated.

[0055] (2) Test methods and results The bacterial suspension prepared by the above method was added to the example medium (Table 1 Example 1-1) and the comparative example medium (Table 1 Comparative Example) shown in Table 1 so that the total volume was 5 mL. The amount of bacteria in the medium after adding bacteria was 5 x 10 7 It was cells.

[0056] In addition, Example 1-2 was prepared by adjusting the content of Falcorex (registered trademark) Kiwi B (kiwi 1,3-butylene glycol extract, Ichimaru Falcos) in Example 1-1 to 0.1%. In addition, Example 2 was prepared by replacing Falcorex (registered trademark) Kiwi B (kiwi 1,3-butylene glycol extract, Ichimaru Falcos) in Example 1-1 with Yuzu Ceramide B (yuzu 1,3-butylene glycol extract, Ichimaru Falcos).

[0057] [Table 1]

[0058] After the addition, shaking culture was carried out under aerobic conditions at 37°C.

[0059] From the start of the shaking culture, OD660 was measured every hour using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)). The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measurement time from the OD660 measurement value at the start of shaking culture. The results are shown in FIGS. 1 to 3 and Table 2.

[0060] [Table 2]

[0061] (3) Discussion The results of Example 1 showed that the amount of a specific fungus can be specifically controlled by using a kiwi extract. More specifically, the results of Example 1 showed that the kiwi extract has an effect of promoting the amount of S. hominis fungus.

[0062] Furthermore, the results of Example 2 showed that the amount of a specific bacterial cell can be specifically controlled by using a yuzu extract. More specifically, it was found that the use of yuzu extract can promote the bacterial count of S. hominis.

[0063] <Test Example 2> Relationship between skin condition parameters and S. hominis The following shows various test results that support the uses of preferred embodiments of the present invention.

[0064] The association between the following skin condition parameters and S. hominis was investigated: Unless otherwise specified, the bacterial amount described below is the number of reads and represents the amount of S. hominis present.

[0065] <1> Cultivation of strains In this example, Staphylococcus hominis GTC485 strain (hereinafter also simply referred to as S. hominis) was used as Staphylococcus hominis.

[0066] The obtained S. hominis was cultured in BBL-Tripticase Soybean Agar medium (Becton Dickinson, ND, USA) at pH 7.3 under aerobic conditions at 37°C. The cultured cells were collected, suspended in a 10% skim milk solution, and then vacuum-freeze-dried using the L-drying method to obtain S. hominis freeze-dried material (approximately 10 11 The freeze-dried S. hominis thus produced was used in the following tests.

[0067] <2> Test method, measurement of S. hominis amount and skin condition

[0068] <2-1> Test method (1) Subjects The subjects were 11 healthy Japanese women in their 30s who did not have any diseases such as atopic dermatitis.

[0069] (2) Test method (2-1) Production of S. hominis-containing cosmetics (Examples) and S. hominis-free cosmetics (Comparative Examples, Placebo Cosmetics) The freeze-dried S. hominis was suspended in 10 mL of distilled water to form a suspension (S. hominis content: approximately 10 10 CFU / mL) was prepared. 1 mL of the prepared suspension was mixed with 1 mL of lotion (containing polyethylene glycol, dipropylene glycol, glycerin, diglycerin, potassium hydroxide, and water), and the resulting mixture was used as a cosmetic containing S. hominis (Example, S. hominis content: approximately 5 × 10 9 CFU / mL) were produced. In addition, a cosmetic product not containing S. hominis (comparison example, placebo cosmetic product) was produced using freeze-dried skim milk not containing S. hominis instead of freeze-dried S. hominis in the same manner as the cosmetic product containing S. hominis.

[0070] (2-2) Application of cosmetics The subject applied 0.2 mL of the cosmetic containing S. hominis (Example) to one of the cheeks and 0.2 mL of the cosmetic not containing S. hominis (Comparative Example, placebo cosmetic) to the other cheek. 9 CFU) was applied twice a week for one month. One month after the start of application of the cosmetic preparation, the skin condition and the amount of S. hominis on the cheeks were measured using the following methods.

[0071] <2-2> Measurement of S. hominis quantity and skin condition (1) Measurement and evaluation of the amount of S. hominis in the cheek The amount of S. hominis on each cheek was measured using the following method before the start of cosmetic application, during the cosmetic application period, and at the end of the cosmetic application test (one month after the start of cosmetic application).

[0072] Bacterial flora was collected from the cheeks of female subjects using a bacterial collection sticker or cotton swab (Swab method). DNA was then extracted from the collected bacterial flora, and S. hominis was analyzed by OTU (Operational Taxonomic Unit) analysis. The amount of S. hominis was measured by counting the number of reads belonging to each OTU.

[0073] The amount of S. hominis for each subject at the time of each cosmetic application test was calculated by setting the number of S. hominis leads before application of the cosmetic as 1, and calculating the ratio of leads one week, two weeks, three weeks, and one month after application. The results were expressed as the mean ± standard error (se) for each subject (N = 11). Statistical analysis was performed based on two-way analysis of variance (*P < 0.05).

[0074] (2) Measurement and evaluation of the number of noticeable pores Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable pores on the cheeks was evaluated using the following method.

[0075] First, skin images were taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield), and the number of noticeable pores on the subject was counted through image analysis. The difference between the number of pores measured at the end of the cosmetic application test and the number of pores before the start of cosmetic application was calculated, and this was taken as the change in the number of noticeable pores (Δnumber of noticeable pores).

[0076] Here, the larger the value of the change in the number of noticeable pores (Δ number of noticeable pores), the more the number of noticeable pores has decreased. The results were expressed as the mean ± standard error (se) of the change in the number of noticeable pores for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0077] (3) Measurement and evaluation of melanin index Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the melanin index of the cheeks was evaluated by the following method.

[0078] First, absorbance (A) was measured using a spectrophotometer (Konica Minolta Sensing, Inc., CM2600d), and then the melanin index (MI) was calculated using the formula (MI = A 640 -A 670 The melanin index of each subject was measured by calculating the melanin index using the formula (Feather's formula). The difference between the measured melanin index at the end of the cosmetic application test and the melanin index before the start of cosmetic application was calculated and used as the change in melanin index (Δmelanin index).

[0079] Here, a larger value of the change in melanin index (Δmelanin index) indicates a greater decrease in the melanin index. The results were expressed as the mean ± standard error (se) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0080] (4) Measurement and evaluation of the number of wrinkles Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable wrinkles on the cheeks was evaluated using the following method.

[0081] First, skin images were taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield), and the number of wrinkles on the subject was counted through image analysis. The difference between the number of wrinkles measured at the end of the cosmetic application test and the number of wrinkles before the start of cosmetic application was calculated, and this was taken as the change in the number of wrinkles (Δ number of wrinkles).

[0082] Here, a larger value of the change in the number of wrinkles (Δnumber of wrinkles) indicates a greater reduction in the number of wrinkles. The results were expressed as the mean ± standard error (se) of the change in the number of wrinkles (Δ number of wrinkles) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0083] <2-3>Result The results are shown in Tables 3 and 4 and FIGS.

[0084] [Table 3]

[0085] [Table 4]

[0086] As shown in Table 3 and Figure 4, it was found that the amount of S. hominis increased in subjects who continuously used cosmetics containing S. hominis.

[0087] Furthermore, as shown in Table 4 and Figure 5, the change in the number of noticeable pores (Δ number of noticeable pores) was greater on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the number of noticeable pores was reduced on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis.

[0088] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores.

[0089] Furthermore, as shown in Table 4 and Figure 6, the subjects who continuously used cosmetics containing S. hominis had a larger change in melanin index (Δmelanin index) than the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the melanin index of the cheeks of subjects who continuously used cosmetics containing S. hominis was reduced compared to the cheeks of subjects who used cosmetics not containing S. hominis.

[0090] From the above, it was found that S. hominis has the effect of reducing melanin.

[0091] As shown in Table 5 and Figure 7, the change in the number of wrinkles (Δ number of wrinkles) was greater on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the number of wrinkles was reduced on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis.

[0092] From the above, it was found that S. hominis has the effect of improving wrinkles.

[0093] Furthermore, as shown in the above-mentioned test, the use of kiwi extract and / or yuzu extract has the effect of promoting the bacterial count of S. hominis.

[0094] That is, by using kiwi extract and / or yuzu extract, it is possible to provide a composition that exhibits the above-mentioned skin condition improving effects in a complex manner. [Industrial Applicability]

[0095] The present invention can be applied to cosmetics.

Claims

1. Staphylococcus hominis, containing kiwi extract and / or yuzu extract as active ingredients A bacterial count regulator for promoting the bacterial count of Staphylococcus hominis.

2. A method for treating Staphylococcus hominis ( A bacterial load-regulating composition for external application to the skin for promoting the bacterial load of Staphylococcus hominis.

3. Rough skin that is not atopic dermatitis and / or sebum on skin that is not atopic dermatitis The composition for external application to skin for regulating bacterial load according to claim 2, for preventing or improving an increase in the amount of bacteria.

4. The topical composition for skin application for regulating bacterial load according to claim 2 or 3, for improving skin conditions caused by age spots, dullness, pigmentation, post-inflammatory pigmentation, sun spots, or an increase in the number of noticeable pores.

5. The bacterial load-regulating composition for external application to skin according to any one of claims 2 to 4, for improving wrinkles.

6. The bacterial load-regulating composition for external use on skin according to any one of claims 2 to 5, which is a cosmetic.

7. The bacterial load-regulating composition for external application to skin according to any one of claims 2 to 5, which is a pharmaceutical product.

Images